Question explored with the scientific record
was the risk benefit of covid vaccine?
The risk-benefit of COVID-19 vaccination depends heavily on age, prior infection, and the specific outcome you measure. For older adults, the evidence shows a clear mortality benefit. For younger people, the benefit is smaller and the known harms are more concentrated.
The strongest evidence for a mortality benefit comes from a Norwegian study of 4.6 million adults, which found that people who received three or more mRNA doses had about a 60% lower rate of all-cause death compared to unvaccinated people, after adjustment [3]. A Hungarian study of 6.4 million adults, which tried to correct for the "healthy vaccinee" bias (the fact that healthier people are more likely to get vaccinated), still found a 49% to 75% reduction in all-cause mortality during the epidemic wave [4]. A Danish study of 100,000 heart failure patients found a small but significant reduction in 90-day mortality after vaccination [7].
But several studies raise serious questions. A UK analysis of official ONS data found that all-cause and non-COVID mortality rates in vaccinated people started lower but rose over time, crossing the unvaccinated rate in some age groups between late 2022 and early 2025 [2]. A US county-level study of over 3,000 counties found that higher vaccination uptake was associated with higher all-cause excess mortality in 2022 and 2023, even after adjusting for past mortality [1]. A European ecological study of 31 countries found the same pattern: higher 2021 vaccination rates predicted larger monthly mortality increases in 2022 [5]. A nursing home study found that elevated mortality after a COVID-19 infection lasted longer in vaccinated residents (up to 5 weeks) than in unvaccinated residents (1 week) [6].
The known harms are real. Myocarditis and pericarditis are rare but documented complications of mRNA vaccines, most common in young males after the second dose [8][9][10][11]. A Thai study found 4.43 cases per 100,000 doses in 12-17 year old males after the second dose [8]. A US analysis estimated 12.6 cases per million doses in 12-39 year olds [11]. These cases are usually mild and self-limited, but the long-term cardiac outcomes are not well studied.
| Population | All-cause mortality benefit (adjusted) | Key harms |
|---|---|---|
| Adults 65+ (3+ doses) | ~58% lower rate vs unvaccinated [3] | Myocarditis rare, higher in young males |
| Adults 45-64 (3+ doses) | ~61% lower rate vs unvaccinated [3] | Myocarditis risk lower than in young |
| Adults 18-44 (3+ doses) | ~58% lower rate vs unvaccinated [3] | Myocarditis risk highest in this age group |
| Nursing home residents | Mortality elevated longer after infection in vaccinated [6] | Signal of possible harm in frail elderly |
| All ages (ecological studies) | Higher vaccination linked to higher excess mortality [1][5] | Confounding cannot be ruled out |
My call: for people over 65, the evidence supports a net mortality benefit from vaccination, especially the primary series and first booster. For younger people, especially males under 40, the benefit is smaller and the risk of myocarditis, though rare, is real. The long-term safety data is thin, and the ecological studies showing higher mortality in more-vaccinated populations are a signal that deserves investigation, not dismissal. Confidence: moderate.
Sources used 11
-
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…
DOI: 10.12688/f1000research.154058.2 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study
In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…
DOI: 10.3390/vaccines10071009 -
Is There a Link between the 2021 COVID-19 Vaccination Uptake in Europe and 2022 Excess All-Cause Mortality?
Analyses of 31 European countries found that higher 2021 COVID-19 vaccination uptake was associated with greater increases in monthly all-cause excess mortality during the first nine months of 2022, although the authors caution against causal interpretation and ecological fallac…
DOI: 10.21276/apjhs.2023.10.1.6 -
Temporal patterns of all-cause mortality among U.S. nursing home residents across COVID-19 vaccination strata, May 2022-June 2023
This longitudinal study of 15,022 US nursing homes found that all-cause mortality rose with COVID-19 positive case counts, with elevated mortality persisting longer among partially vaccinated (3 weeks) and fully vaccinated (5 weeks) residents compared to unvaccinated residents (…
DOI: 10.18103/mra.v14i3.7380 -
Risk of worsening heart failure and all-cause mortality following mRNA COVID-19 vaccination in patients with heart failure: a Danish nationwide real-world safety study
In a nationwide Danish cohort of 101,786 patients with heart failure, SARS-CoV-2 mRNA vaccination was associated with a lower 90-day all-cause mortality risk compared with a matched 2019 unvaccinated cohort and with no difference in worsening heart failure, myocarditis, or venou…
DOI: 10.1093/eurheartj/ehac544.881 -
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
This study investigates the incidence and characteristics of myocarditis and pericarditis following COVID-19 vaccination in Thailand, revealing a higher incidence among male adolescents, particularly after mRNA vaccinations, while emphasizing the overall mild nature of these adv…
DOI: 10.3390/vaccines11040749 -
Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre
Seventeen cardiac adverse events after COVID-19 mRNA vaccination (mostly men, median age 38) generally met ESC diagnostic criteria and mostly resolved; 94% were deemed possibly vaccine-related by the pharmacovigilance centre.
DOI: 10.21542/gcsp.2021.18 -
COVID-19 vaccination–related cardiovascular complications
This narrative review finds COVID-19 vaccination is associated with rare cardiovascular complications, especially mRNA vaccine myocarditis in young men and adenoviral vaccine VITT/VTE, but myocarditis and thrombosis are more common after SARS-CoV-2 infection and benefits outweig…
DOI: 10.36011/cpp.2023.5.e17 -
Myocarditis With COVID-19 mRNA Vaccines
This narrative review characterizes myocarditis/pericarditis as a rare complication of COVID-19 mRNA vaccination, particularly in young males after the second dose, with a generally self-limited course and a favorable overall benefit-risk balance supporting universal vaccination.
DOI: 10.1161/circulationaha.121.056135